Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

Aged; Cost-Benefit Analysis; Estrogen Replacement Therapy/economics; Female; Health Care Costs; Humans; Middle Aged; Models, Econometric; Osteoporosis/economics/therapy; Osteoporosis, Postmenopausal/economics/therapy

Disciplines :

Endocrinology, metabolism & nutrition
Special economic topics (health, labor, transportation...)

Author, co-author :

Zethraeus, N.

Ben Sedrine, Wafa ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Caulin, F.

Corcaud, S.

Gathon, Henry-Jean ; Université de Liège - ULiège > HEC - École de gestion de l'ULiège > Economie générale et gestion publique

Haim, M.

Johnell, O.

Jonsson, B.

Kanis, J. A.

Tsouderos, Yannis ; Université de Liège - ULiège > Département de pharmacie

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis

Publication date :

2002

Journal title :

Osteoporosis International

ISSN :

0937-941X

eISSN :

1433-2965

Publisher :

Springer-Verlag London, Godalming, United Kingdom

Volume :

Issue :

Pages :

841-857

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 December 2009

Statistics

Number of views

157 (15 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Willis M, Ödegaard K, Persson U, et al. A cost-effectiveness model of Tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women. Clin Pharmacoecon 2001;21:115-27.
Henriksson F, Fredrikson S, Masterman T, Jönsson B. Costs, quality of life and disease severity in multiple sclerosis - A crosssectional study in Sweden. Eur J Neurol 2001;8:27-35.
Henriksson F, Agardh C-D, Berne C et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2001;248:387-96.
Johannesson M, Jönsson B. Economic evaluation of osteoporosis prevention. Health Policy 1993;24:103-24.
Eckerlund I, Johannesson M, Johansson P-O et al. Value for money? A contingent valuation study of the optimal size of the Swedish health care budget. Health Policy 1995;34:135-43.
Johansson P-O. Evaluating Health Risks. An Economic Approach. Cambridge: Cambridge University Press, 1995.
Zethraeus N, Johannesson M, Henriksson P et al. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1997;104:1191-5.
Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J Public Econ 1973;2:147-57.
Drummond MF, O'Brien B, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications, 1997.
Brooks R and the EuroQol group. EuroQol: The current state of play. Health Policy 1996;37:53-72.
Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
Oleksik A, Lips P, Dawson A, et al. Health related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fracure. J Bone Miner Res 2000;15:1384-92.
Gold MR, Siegel JE, Russell LB et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
Johannesson M. The concept of cost in the economic evaluation of health care. Int J Technol Assessment Health Care 1994;10:675-82.
Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997;16:33-64.
Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993;13:322-38.
Weinstein MC. Estrogen use in postmenopausal women: Costs, risks, and benefits. N Engl J Med 1980;303:308-16.
Weinstein MC, Schiff I. Cost-effectiveness of hormone replacement therapy in the menopause. Obstet Gynecol Surv 1983;38:445-55.
Weinstein MC, Tosteson AN. Cost-effectiveness of hormone replacement. Ann NY Acad Sci 1990;592:162-72.
Tosteson A, Rosenthal DI, Melton LJ, et al. Cost-effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement theory. Ann Intern Med 1990;113:594-603.
Tosteson A, Weinstein MC. Cost-effectiveness of hormone replacement therapy after the menopause. Baillière's Clin Obstet Gynaecol 1991;5:no. 4.
Cheung AP, Wren BG. A cost-effective analysis of hormone replacement therapy in the menopause. MJA 1992;156:312-16.
Daly E, Roche M, Barlow D et al. HRT: An analysis of benefits, risks and costs. Br Med Bull 1992;48:368-400.
Jönsson B, Hedbrant J, Johnell O. A Computer Simulation Model to Analyse the Cost-Effectiveness of Fracture Prevention of Osteoporosis. EFI Research paper Nr 6525, 1993.
Jönsson B, Christiansen C, Johnell O et al. The cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 1995;5:136-42.
Tosteson, A. Hormone replacement therapy: Benefit, risk and cost considerations. J Clin Pharmacol 1994;34:719-22.
Geelhoed E, Harris A. Cost-effectiveness analysis of hormone replacement therapy and life style intervention for hip fracture. Aust J Public Health 1994;18:153-60.
Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Vol. I: Cost-Effectiveness Analysis, Vol. II: Evidence on Benefits, Risks and Costs. US Government Printing Office, 1995.
Daly E, Vessey MP, Barlow D et al. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996;23:247-59.
Zethraeus N, Johannesson M, Jönsson B. A Computer Model to Analyse the Cost Effectiveness of Hormone Replacement Therapy. EFI Research Paper No 6578 January 1998.
Zethraeus N, Johannesson M, Jönsson B et al. A computer model to analyse the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 1999;15:352-65.
Jönsson B, Kanis J, Dawson A, et al. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 1999;10:193-9.
Kanis JA, Dawson A, Oden A et al. Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001;12:356-61.
Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis. Bone (in press).
Tosteson ANA, Jönsson B, Grima DT et al. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporos Int 2001;12:849-57.
Johnell O, Jönsson B, Jönsson L et al. Cost-effectiveness of Fosamax (alendronate) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (in press).
Melton LJ. Kan SH, Wahner HW, et al. Life time fracture risk: An approach to hip fracture risk assessment based on bone mineral density and age. J Clin Epidemiol 1988;41:985-94.
Grady D, Rubin SM, Petitti D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992:1016-37.
Perth Monica Data Book 1984-1990. Perth: University of Western Australia, 1992.
Reznik RB, Goldstein GB, Ring I et al. The determination of the incidence of acute myocardial infarction from hospital morbidity records. J Chron Dis 1984;37:733-42.
Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
Brinton LA, Hoover R, Fraumeni JF. Menopausal oestrogens and breast cancer risk: An expanded case-study. Br J Cancer 1986;54:825-32.
Johannesson M, Hedbrant J, Jönsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Informatics 1991;16:355-62.
Zethraeus N, Lindgren P, Johnell O, et al. A Computer Model to Analyse the Cost-Effectiveness of Hormone Replacement Therapy a Revised Version. SSE/EFI Working Paper Series in Economics and Finance, at the Stockholm School of Economics, 2000, Working paper No. 368.
Zethraeus N, Gerdtham U-G. Estimating the costs of fracture and potential savings. Int J Technol Assess Health Care 1998;14:255-67.
Tosteson A. et al. Challenges for model-based economic evaluations of post-menopausal osteoporosis interventions. Osteoporos Int 2001;12:849-57.
Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500.
Torgerson DJ, Reid DM. The economics of osteoporosis and its prevention. A review. PharmacoEconomics 1997;11:126-38.
Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women. A prospective study. Arch Intern Med 1999;159:1215-20.
WHO (World Health Organization). Recommendations for Health Economics Evaluations of Interventions in Osteoporosis. Liège, Belgium: WHO Collaborating Centre for Public Health Aspects of Osteoporosis and other Rheumatic Diseases, 1999.
Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-40.
Almbrand B, Johannesson M, Sjöstrand B et al. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus. Eur Heart J 2000;21:733-9.
Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention. Eur Heart J 2001;22:919-25.
National Osteoporosis Foundation. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and costeffectiveness analysis. Osteoporos Int 1998;8:1-88.
Akehorst R, Anderson P, Brazier J, et al. Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Pharmacoeconomics 2000;17:443-4.
Sculpher M, Fenwick E, and Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000;17:461-77.